NXI 101
Alternative Names: NXI-101Latest Information Update: 12 Jul 2024
At a glance
- Originator NEX-I
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Cytokine stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Mar 2024 Preclinical trials in Solid tumours in South Korea (Parenteral)
- 06 Mar 2024 Ono Pharmaceutical entered into a license agreement with NEX-I, Inc. for NXI-101